Ethambutol
- Generic Name
- Ethambutol
- Brand Names
- Etibi, Myambutol
- Drug Type
- Small Molecule
- Chemical Formula
- C10H24N2O2
- CAS Number
- 74-55-5
- Unique Ingredient Identifier
- 8G167061QZ
- Background
Ethambutol is a bacteriostatic agent indicated alongside medications such as isoniazid, rifampin, and pyrazinamide in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of Mycobacterium tuberculosis.
Ethambutol was granted FDA approval on 6 November 1967.
- Indication
Ethambutol is indicated in combination with other anti-tuberculosis drugs in the treatment of pulmonary tuberculosis. Ethambutol is commonly used in combination with isoniazid, rifampin, and pyrazinamide.
- Associated Conditions
- Mycobacterium Avium Intracellulare Complex (MAC), Mycobacterium Infections, Pulmonary Tuberculosis (TB)
Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis
- Conditions
- Mild Spinal Tuberculosis
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Shandong University
- Target Recruit Count
- 300
- Registration Number
- NCT06917495
- Locations
- 🇨🇳
Shandong Public Health Clinical Center, Jinan, China
A PAN-USR TB Multi-Center Trial
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Shenzhen Third People's Hospital
- Target Recruit Count
- 610
- Registration Number
- NCT06905522
Shortened Regimen for Drug-susceptible TB in Children
- Conditions
- Tuberculosis, Lymph NodeMycobacterium TuberculosisTuberculosisTuberculosis, Pulmonary
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 860
- Registration Number
- NCT06253715
- Locations
- 🇮🇳
Indian Council of Medical Research - National Institute for Research in Tuberculosis, Chennai, India
🇮🇳Dr. D.Y. Patil Medical College, Hospital and Research Center, Pune, India
🇮🇩Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-04-23
- Target Recruit Count
- 315
- Registration Number
- NCT06192160
- Locations
- 🇧🇼
12701, Gaborone CRS, Gaborone, Botswana
🇧🇷12201, Hospital Nossa Senhora da Conceicao CRS, Porto Alegre, Brazil
🇧🇷12101, Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio De Janeiro, Brazil
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
- Conditions
- Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2023-11-02
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- University College, London
- Target Recruit Count
- 2500
- Registration Number
- NCT06114628
- Locations
- 🇿🇦
TASK Eden, George, South Africa
🇹🇿NIMR Mbeya, Mbeya, Tanzania
🇿🇦TASK Brooklyn, Cape Town, South Africa
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
- Conditions
- Pulmonary TuberculosisRifampicin-resistant Tuberculosis
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 186
- Registration Number
- NCT06081361
- Locations
- 🇨🇳
Fuzhou Pulmonary Hospital of Fujian, Fuzhou, China
🇨🇳People's Hospital of Linyi, Linyi, China
🇨🇳Fourth People's Hospital of Nanning, Nanning, China
A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin, and Ethambutol in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Spero Therapeutics
- Target Recruit Count
- 39
- Registration Number
- NCT05966688
- Locations
- 🇺🇸
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
- Conditions
- Tuberculosis, PulmonaryTuberculosis Infection
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2025-02-11
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 288
- Registration Number
- NCT05766267
- Locations
- 🇺🇸
TBTC Site 26 Seattle & King County TB Control Program, Seattle, Washington, United States
🇺🇸TBTC Site 64A New York City Department of Health and Mental Hygiene- Corona Chest Center, Jackson Heights, New York, United States
🇺🇸TBTC Site 63 San Antonio VA Medical Center (South Texas Group), San Antonio, Texas, United States
Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB
- Conditions
- Tuberculosis, PulmonaryHIV
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 156
- Registration Number
- NCT05556746
- Locations
- 🇭🇹
GHESKIO, Port-au-Prince, Haiti
🇿🇦University of Cape Town, Cape Town, South Africa
Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment
- Conditions
- Tuberculosis, Pulmonary
- Interventions
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- First Affiliated Hospital of Zhejiang University
- Target Recruit Count
- 620
- Registration Number
- NCT05454345
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.